查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1584624

CAR-T細胞療法的全球市場：按藥物適應症、按適應症、按最終用戶、按地區、趨勢分析、競爭格局、預測，2019-2030年

CAR-T Cell Therapy Market, By Drug Indication; By Indication; By End User; By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2030
出版日期: | 出版商: Blueweave Consulting | 英文 418 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

到 2030 年，全球 CAR-T 細胞療法市場將擴大 6.2 倍，達到 570 億美元

由於癌症發病率不斷上升、對標靶治療的需求激增以及技術進步的迅速採用，全球 CAR-T 細胞治療市場正在蓬勃發展。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，2023 年全球 CAR-T 細胞療法市場規模以金額為準91.1 億美元。 BlueWeave預測，在2024年至2030年的預測期內，全球CAR-T細胞治療市場規模將以30.20%的複合年成長率穩定成長，到2030年將達到568億美元。全球 CAR-T 細胞治療市場由幾個關鍵因素推動，例如癌症盛行率的增加需要創新治療以及對 CAR-T 療法的需求不斷增加。 CAR-T技術的進步將提高治療的有效性和安全性。對針對性和個人化治療的需求不斷成長，進一步推動了市場的成長。此外，臨床試驗活動和法律規範的活性化正在促進研究和開發，促進市場擴張。

機會 - 擴展到其他適應症

隨著新法規的擴展，全球 CAR-T 細胞治療市場正在成長。 CAR-T療法最初是針對白血病，現在正在研究針對固體癌和其他疾病。廣泛的准入使患者能夠獲得並推動市場。正在進行的研究和臨床試驗旨在提高 CAR-T 療法對這些疾病的療效，並推動市場擴張。

地緣政治緊張局勢加劇對全球 CAR-T 細胞治療市場的影響

地緣政治緊張局勢的加劇可能會擾亂供應鏈並增加投入成本，進而影響全球 CAR-T 細胞治療市場。貿易限制以及政治和經濟不穩定可能會減緩生產和分配。這些挑戰可能迫使製造商尋找新的供應商並改變流程，從而提高消費者的價格並影響市場成長。

Yescarta 在全球 CAR-T 細胞治療市場佔有主要佔有率

由於其對某些血癌，特別是瀰漫性大 B 細胞淋巴瘤 (DLBCL) 的高效功效，Axicabtagene Ciloleucel (Yescarta) 細分市場在全球 CAR-T 細胞療法市場中佔據最大佔有率。 Yescarta在臨床試驗中的成功以及在各個地區的廣泛採用為其在市場上的領先地位做出了貢獻。全球CAR-T細胞療法市場的其他主要適應症包括Brexucabtagene Autoleucel（Tecartus）、Ciltacabtagene Autoleucel（Carvykti）、Idecabtagene Vicleucel（Abecma）、Lisocabtagene Maraleucel（Breyanzi）和Tisagenlecleucel（Kymah）。

競爭格局

全球CAR-T細胞治療市場競爭激烈，許多企業爭奪更大的市場佔有率。這些公司正在利用各種策略在全球 CAR-T 細胞治療市場中佔有一席之地，包括增加對研發活動的投資、併購、合資、聯盟、許可協議以及新產品和服務的發布，並進一步加強這項策略。

本報告的詳細分析提供了有關全球 CAR-T 細胞治療市場的成長潛力、未來趨勢和統計數據的資訊。它還重點關注推動市場總規模預測的因素。該報告致力於提供全球CAR-T細胞治療市場的最新技術趨勢以及產業見解，以幫助決策者做出策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第 2 章執行摘要

第3章 全球CAR-T細胞治療市場洞察

  • 最終用戶價值鏈分析
  • DROC分析
    • 生長促進因子
      • 癌症發生率上升
      • 細胞工程和基因重組技術的不斷進步
      • 有利的監管地位：CAR-T細胞療法
      • 製藥公司、生技公司和投資者的興趣增加
    • 抑制因素
      • CAR-T細胞治療高成本
      • CAR-T 細胞療法的可用性和可及性通常僅限於有限數量的患者。
      • CAR-T 細胞療法相關的潛在副作用
    • 機會
      • 擴展到新的適應症
      • CAR-T細胞療法與其他治療方法結合
      • 基因組學和個人化醫療的進展
    • 任務
      • 與製造 CAR-T 細胞療法相關的製造挑戰
      • 確保 CAR-T 細胞治療的適當報銷
  • 科技進步/最新趨勢
  • 法律規範
  • 波特五力分析

第4章全球CAR-T細胞治療市場：行銷策略

第5章全球CAR-T細胞治療市場：價格分析

第6章全球CAR-T細胞治療市場：區域分析

  • 全球 CAR-T 細胞治療市場，區域分析，2023 年
  • 2024-2030年全球CAR-T細胞治療市場吸引力分析

第7章 全球CAR-T細胞治療市場概況

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按藥物適應症
      • Axicabtagene Ciloleucel (Yescarta)
      • Brexucabtagene Autoleucel (Tecartus)
      • Ciltacabtagene Autoleucel (Carvykti)
      • Idecabtagene Vicleucel (Abecma)
      • Lisocabtagene Maraleucel (Breyanzi)
      • Tisagenlecleucel (Kymriah)
      • 其他
    • 按指示
      • 急性淋巴性白血病
      • 非何傑金氏淋巴瘤
      • 多發性骨髓瘤
    • 按最終用戶
      • 醫院
      • 腫瘤治療中心
    • 按地區
      • 北美洲
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第8章 北美CAR-T細胞治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按藥物適應症
    • 按指示
    • 按最終用戶
    • 按國家/地區
      • 美國
      • 加拿大

第9章歐洲CAR-T細胞治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按藥物適應症
    • 按指示
    • 按最終用戶
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第10章亞太CAR-T細胞治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按藥物適應症
    • 按指示
    • 按最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 亞太地區其他地區

第11章拉丁美洲CAR-T細胞治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按藥物適應症
    • 按指示
    • 按最終用戶
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第12章中東和非洲CAR-T細胞治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按藥物適應症
    • 按指示
    • 按最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 其他中東/非洲

第13章競爭格局

  • 主要參與者及其產品列表
  • 2023年全球CAR-T細胞治療企業市場佔有率分析
  • 透過管理參數進行競爭基準基準化分析
  • 重大策略發展（合併、收購、聯盟等）

第14章 地緣政治緊張局勢升級對全球CAR-T細胞治療市場的影響

第15章 公司簡介（公司簡介、財務矩陣、競爭格局、關鍵人員、主要競爭對手、聯絡方式、策略展望、SWOT分析）

  • Bristol-Myers Squibb
  • Sorrento Therapeutics, Inc.
  • Celgene Corporation
  • Merck &Co., Inc.
  • Novartis AG
  • Celyad Oncology
  • Juno Therapeutics, Inc.
  • Autolus Therapeutics
  • Cellectis
  • Miltenyi Biotech
  • Intellia Therapeutics
  • Pfizer, Inc.
  • 其他主要企業

第16章 主要策略建議

第17章調查方法

簡介目錄
Product Code: BWC24781

Global CAR-T Cell Therapy Market Zooms 6.2X to Touch Whopping USD 57 Billion by 2030

Global CAR-T Cell Therapy Market is thriving due to increasing prevalence of cancer, a spurring demand for targeted therapies, and rapid adoption of technological advancements.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global CAR-T Cell Therapy Market size by value at USD 9.11 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global CAR-T Cell Therapy Market size to expand at a robust CAGR of 30.20% reaching a value of USD 56.80 billion in 2030. Global CAR-T Cell Therapy Market is driven by several key factors, including the increasing prevalence of cancer necessitates innovative treatments, boosting demand for CAR-T therapies. Advancements in CAR-T technology enhance treatment efficacy and safety. Growing demand for targeted and personalized therapies further propels market growth. Additionally, rising clinical trial activities and supportive regulatory frameworks encourage research and development, fostering market expansion.

Opportunity - Expansion into other Indications

Global CAR-T Cell Therapy Market is growing with the expansion of new regulations. Initially focused on leukemia, CAR-T therapies are now being investigated for solid tumors and other diseases. Wide access enables patients to access and drives the market. Ongoing research and clinical trials are aimed at increasing the efficacy of CAR-T therapies for the conditions, driving market expansion.

Impact of Escalating Geopolitical Tensions on Global CAR-T Cell Therapy Market

Increasing geopolitical tensions could impact Global CAR-T Cell Therapy Market by disrupting supply chains and increasing input costs. Trade restrictions and political and economic instabilities could delay production and distribution. These challenges are forcing manufacturers to seek new sources and change processes, potentially increasing prices for consumers and affecting market growth.

Yescarta Holds Major Share of Global CAR-T Cell Therapy Market

The Axicabtagene Ciloleucel (Yescarta) segment accounts for the largest market share of Global CAR-T Cell Therapy Market by drug indication, due to its high efficacy in treating certain types of blood cancers, particularly diffuse large B-cell lymphoma (DLBCL). Yescarta's success in clinical trials and its widespread adoption in various regions contribute to its leading position in the market. The other major drug indication segments in Global CAR-T Cell Therapy Market include Brexucabtagene Autoleucel (Tecartus), Ciltacabtagene Autoleucel (Carvykti), Idecabtagene Vicleucel (Abecma), Lisocabtagene Maraleucel (Breyanzi), and Tisagenlecleucel (Kymriah).

Competitive Landscape

Global CAR-T Cell Therapy Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Bristol-Myers Squibb, Sorrento Therapeutics, Inc., Celgene Corporation, Merck & Co., Inc., Novartis AG, Celyad Oncology, Juno Therapeutics, Inc., Autolus Therapeutics, Cellectis, Miltenyi Biotech, Intellia Therapeutics, and Pfizer, Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global CAR-T Cell Therapy Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global CAR-T Cell Therapy Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technological trends in Global CAR-T Cell Therapy Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the Market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global CAR-T Cell Therapy Market Insights

  • 3.1. End User Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Continuous advancements in cell engineering and genetic modification techniques
      • 3.2.1.3. Favorable regulatory landscape: for CAR-T cell therapy
      • 3.2.1.4. Growing interest from pharmaceutical companies, biotech firms, and investors
    • 3.2.2. Restraints
      • 3.2.2.1. High costs of CAR-T cell therapy
      • 3.2.2.2. Limited availability and access to CAR-T cell therapy is often restricted to a limited number of patients.
      • 3.2.2.3. Potential side effects associated with CAR-T cell therapy
    • 3.2.3. Opportunities
      • 3.2.3.1. Expansion into new indications
      • 3.2.3.2. Combining CAR-T cell therapy with other treatments
      • 3.2.3.3. Advancements in genomics and personalized medicine
    • 3.2.4. Challenges
      • 3.2.4.1. Manufacturing challenges associated with the production of CAR-T cell therapies
      • 3.2.4.2. Ensuring adequate reimbursement for CAR-T cell therapy
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global CAR-T Cell Therapy Market: Marketing Strategies

5. Global CAR-T Cell Therapy Market: Pricing Analysis

6. Global CAR-T Cell Therapy Market: Geography Analysis

  • 6.1. Global CAR-T Cell Therapy Market, Geographical Analysis, 2023
  • 6.2. Global CAR-T Cell Therapy, Market Attractiveness Analysis, 2024-2030

7. Global CAR-T Cell Therapy Market Overview

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Indication
      • 7.2.1.1. Axicabtagene Ciloleucel (Yescarta)
      • 7.2.1.2. Brexucabtagene Autoleucel (Tecartus)
      • 7.2.1.3. Ciltacabtagene Autoleucel (Carvykti)
      • 7.2.1.4. Idecabtagene Vicleucel (Abecma)
      • 7.2.1.5. Lisocabtagene Maraleucel (Breyanzi)
      • 7.2.1.6. Tisagenlecleucel (Kymriah)
      • 7.2.1.7. Others
    • 7.2.2. By Indication
      • 7.2.2.1. Acute Lymphoblastic Leukemia
      • 7.2.2.2. Non-Hodgkin Lymphoma
      • 7.2.2.3. Multiple Myeloma
    • 7.2.3. By End User
      • 7.2.3.1. Hospitals
      • 7.2.3.2. Oncology Treatment Centers
    • 7.2.4. By Region
      • 7.2.4.1. North America
      • 7.2.4.2. Europe
      • 7.2.4.3. Asia Pacific (APAC)
      • 7.2.4.4. Latin America (LATAM)
      • 7.2.4.5. Middle East and Africa (MEA)

8. North America CAR-T Cell Therapy Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Indication
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.1.1. By Drug Indication
      • 8.2.4.1.2. By Indication
      • 8.2.4.1.3. By End User
      • 8.2.4.2. Canada
      • 8.2.4.2.1. By Drug Indication
      • 8.2.4.2.2. By Indication
      • 8.2.4.2.3. By End User

9. Europe CAR-T Cell Therapy Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Indication
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Germany
      • 9.2.4.1.1. By Drug Indication
      • 9.2.4.1.2. By Indication
      • 9.2.4.1.3. By End User
      • 9.2.4.2. United Kingdom
      • 9.2.4.2.1. By Drug Indication
      • 9.2.4.2.2. By Indication
      • 9.2.4.2.3. By End User
      • 9.2.4.3. Italy
      • 9.2.4.3.1. By Drug Indication
      • 9.2.4.3.2. By Indication
      • 9.2.4.3.3. By End User
      • 9.2.4.4. France
      • 9.2.4.4.1. By Drug Indication
      • 9.2.4.4.2. By Indication
      • 9.2.4.4.3. By End User
      • 9.2.4.5. Spain
      • 9.2.4.5.1. By Drug Indication
      • 9.2.4.5.2. By Indication
      • 9.2.4.5.3. By End User
      • 9.2.4.6. Belgium
      • 9.2.4.6.1. By Drug Indication
      • 9.2.4.6.2. By Indication
      • 9.2.4.6.3. By End User
      • 9.2.4.7. Russia
      • 9.2.4.7.1. By Drug Indication
      • 9.2.4.7.2. By Indication
      • 9.2.4.7.3. By End User
      • 9.2.4.8. The Netherlands
      • 9.2.4.8.1. By Drug Indication
      • 9.2.4.8.2. By Indication
      • 9.2.4.8.3. By End User
      • 9.2.4.9. Rest of Europe
      • 9.2.4.9.1. By Drug Indication
      • 9.2.4.9.2. By Indication
      • 9.2.4.9.3. By End User

10. Asia Pacific CAR-T Cell Therapy Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Indication
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
      • 10.2.4.1. China
      • 10.2.4.1.1. By Drug Indication
      • 10.2.4.1.2. By Indication
      • 10.2.4.1.3. By End User
      • 10.2.4.2. India
      • 10.2.4.2.1. By Drug Indication
      • 10.2.4.2.2. By Indication
      • 10.2.4.2.3. By End User
      • 10.2.4.3. Japan
      • 10.2.4.3.1. By Drug Indication
      • 10.2.4.3.2. By Indication
      • 10.2.4.3.3. By End User
      • 10.2.4.4. South Korea
      • 10.2.4.4.1. By Drug Indication
      • 10.2.4.4.2. By Indication
      • 10.2.4.4.3. By End User
      • 10.2.4.5. Australia & New Zealand
      • 10.2.4.5.1. By Drug Indication
      • 10.2.4.5.2. By Indication
      • 10.2.4.5.3. By End User
      • 10.2.4.6. Indonesia
      • 10.2.4.6.1. By Drug Indication
      • 10.2.4.6.2. By Indication
      • 10.2.4.6.3. By End User
      • 10.2.4.7. Malaysia
      • 10.2.4.7.1. By Drug Indication
      • 10.2.4.7.2. By Indication
      • 10.2.4.7.3. By End User
      • 10.2.4.8. Singapore
      • 10.2.4.8.1. By Drug Indication
      • 10.2.4.8.2. By Indication
      • 10.2.4.8.3. By End User
      • 10.2.4.9. Vietnam
      • 10.2.4.9.1. By Drug Indication
      • 10.2.4.9.2. By Indication
      • 10.2.4.9.3. By End User
      • 10.2.4.10. Rest of APAC
      • 10.2.4.10.1. By Drug Indication
      • 10.2.4.10.2. By Indication
      • 10.2.4.10.3. By End User

11. Latin America CAR-T Cell Therapy Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Indication
    • 11.2.2. By Indication
    • 11.2.3. By End User
    • 11.2.4. By Country
      • 11.2.4.1. Brazil
      • 11.2.4.1.1. By Drug Indication
      • 11.2.4.1.2. By Indication
      • 11.2.4.1.3. By End User
      • 11.2.4.2. Mexico
      • 11.2.4.2.1. By Drug Indication
      • 11.2.4.2.2. By Indication
      • 11.2.4.2.3. By End User
      • 11.2.4.3. Argentina
      • 11.2.4.3.1. By Drug Indication
      • 11.2.4.3.2. By Indication
      • 11.2.4.3.3. By End User
      • 11.2.4.4. Peru
      • 11.2.4.4.1. By Drug Indication
      • 11.2.4.4.2. By Indication
      • 11.2.4.4.3. By End User
      • 11.2.4.5. Rest of LATAM
      • 11.2.4.5.1. By Drug Indication
      • 11.2.4.5.2. By Indication
      • 11.2.4.5.3. By End User

12. Middle East and Africa CAR-T Cell Therapy Market

  • 12.1. Market Size & Forecast, 2019-2030
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Drug Indication
    • 12.2.2. By Indication
    • 12.2.3. By End User
    • 12.2.4. By Country
      • 12.2.4.1. Saudi Arabia
      • 12.2.4.1.1. By Drug Indication
      • 12.2.4.1.2. By Indication
      • 12.2.4.1.3. By End User
      • 12.2.4.2. UAE
      • 12.2.4.2.1. By Drug Indication
      • 12.2.4.2.2. By Indication
      • 12.2.4.2.3. By End User
      • 12.2.4.3. Qatar
      • 12.2.4.3.1. By Drug Indication
      • 12.2.4.3.2. By Indication
      • 12.2.4.3.3. By End User
      • 12.2.4.4. Kuwait
      • 12.2.4.4.1. By Drug Indication
      • 12.2.4.4.2. By Indication
      • 12.2.4.4.3. By End User
      • 12.2.4.5. South Africa
      • 12.2.4.5.1. By Drug Indication
      • 12.2.4.5.2. By Indication
      • 12.2.4.5.3. By End User
      • 12.2.4.6. Nigeria
      • 12.2.4.6.1. By Drug Indication
      • 12.2.4.6.2. By Indication
      • 12.2.4.6.3. By End User
      • 12.2.4.7. Algeria
      • 12.2.4.7.1. By Drug Indication
      • 12.2.4.7.2. By Indication
      • 12.2.4.7.3. By End User
      • 12.2.4.8. Rest of MEA
      • 12.2.4.8.1. By Drug Indication
      • 12.2.4.8.2. By Indication
      • 12.2.4.8.3. By End User

13. Competitive Landscape

  • 13.1. List of Key Players and Their Offerings
  • 13.2. Global CAR-T Cell Therapy Company Market Share Analysis, 2023
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global CAR-T Cell Therapy Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 15.1. Bristol-Myers Squibb
  • 15.2. Sorrento Therapeutics, Inc.
  • 15.3. Celgene Corporation
  • 15.4. Merck & Co., Inc.
  • 15.5. Novartis AG
  • 15.6. Celyad Oncology
  • 15.7. Juno Therapeutics, Inc.
  • 15.8. Autolus Therapeutics
  • 15.9. Cellectis
  • 15.10. Miltenyi Biotech
  • 15.11. Intellia Therapeutics
  • 15.12. Pfizer, Inc.
  • 15.13. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable